1. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017; 66:839–851.
2. Ng SC, Hilmi IN, Blake A, et al. Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting. Inflamm Bowel Dis. 2018; 24:2431–2441.
3. Meserve J, Aniwan S, Koliani-Pace JL, et al. Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019; 17:1533–1540.
4. Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. Firstand second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020; 18:2179–2191.
5. Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7:161–170.
6. Wang Y, Wang J, Pekow J, et al. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019; 34:2090–2095.
7. Naganuma M, Nagahori M, Fujii T, Morio J, Saito E, Watanabe M. Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD. Inflamm Bowel Dis. 2013; 19:418–422.
8. Shiga H, Takahashi T, Shiraki M, et al. Reduced antiviral seropositivity among patients with inflammatory bowel disease treated with immunosuppressive agents. Scand J Gastroenterol. 2023; 58:360–367.
9. Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA. Rubella. Lancet. 2015; 385:2297–2307.
10. Saitoh A, Okabe N. Progress and challenges for the Japanese immunization program: beyond the “vaccine gap”. Vaccine. 2018; 36:4582–4588.
11. Phadke VK, Bednarczyk RA, Salmon DA, Omer SB. Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis. JAMA. 2016; 315:1149–1158.
12. Cohen ER, Salem M, Ha C. Managing immunosuppressed patients with inflammatory bowel disease during a measles outbreak. Am J Gastroenterol. 2019; 114:1563–1565.
13. Feldman AG, O’Leary ST, Danziger-Isakov L. The risk of resurgence in vaccine-preventable infections due to coronavirus disease 2019-related gaps in immunization. Clin Infect Dis. 2021; 73:1920–1923.
14. Hübschen JM, Gouandjika-Vasilache I, Dina J. Measles. Lancet. 2022; 399:678–690.
15. Kucharzik T, Ellul P, Greuter T, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021; 15:879–913.
16. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019; 68(Suppl 3):s1–s106.
17. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017; 112:241–258.
18. Gisbert JP, Chaparro M. Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol. 2013; 10:277–285.
19. Benchimol EI, Tse F, Carroll MW, et al. Canadian Association of Gastroenterology clinical practice guideline for immunizations in patients with inflammatory bowel disease (IBD) part 1. Live vaccines. Gastroenterology. 2021; 161:669–680.
20. Ishige T, Shimizu T, Watanabe K, et al. Expert consensus on vaccination in patients with inflammatory bowel disease in Japan. J Gastroenterol. 2023; 58:135–157.
21. Wichmann A, Krugliak Cleveland N, Rubin DT. Safety and efficacy of live measles vaccine administered to a Crohn’s disease patient receiving vedolizumab. Am J Gastroenterol. 2016; 111:577.
22. Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018; 53:305–353.
23. Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021; 56:489–526.
24. Caldera F, Misch EA, Saha S, et al. Immunosuppression does not affect antibody concentrations to measles, mumps, and rubella in patients with inflammatory bowel disease. Dig Dis Sci. 2019; 64:189–195.
25. Croce E, Hatz C, Jonker EF, Visser LG, Jaeger VK, Bühler S. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation: a systematic review of randomized trials, observational studies and case reports. Vaccine. 2017; 35:1216–1226.
26. Manser CN, Maillard MH, Rogler G, et al. Vaccination in patients with inflammatory bowel diseases. Digestion. 2020; 101 Suppl 1:58–68.
27. Alexander JL, Kennedy NA, Ibraheim H, et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol. 2022; 7:342–352.
28. Shiga H, Kakuta Y, An K, et al. Response to COVID-19 vaccine is reduced in patients with inflammatory bowel disease, but improved with additional dose. J Gastroenterol Hepatol. 2023; 38:44–51.
29. Liu Z, Alexander JL, Yee Eng K, et al. Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib. J Crohns Colitis. 2024; 18:560–569.
30. Cleveland NK, Rodriquez D, Wichman A, Pan I, Melmed GY, Rubin DT. Many inflammatory bowel disease patients are not immune to measles or pertussis. Dig Dis Sci. 2016; 61:2972–2976.
31. deBruyn JC, Soon IS, Fonseca K, et al. Serologic status of routine childhood vaccines, cytomegalovirus, and Epstein-Barr virus in children with inflammatory bowel disease. Inflamm Bowel Dis. 2019; 25:1218–1226.
32. Khan N, Trivedi C, Aberra F, Pernes T, Yang YX. Safety of recombinant zoster vaccine in patients with inflammatory bowel disease. J Crohns Colitis. 2022; 16:1505–1507.
33. Khan N, Wang L, Trivedi C, et al. Efficacy of recombinant zoster vaccine in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2022; 20:1570–1578.
34. Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18:2392–2403.